BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21654687)

  • 1. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.
    Challberg J; Ashcroft L; Lalloo F; Eckersley B; Clayton R; Hopwood P; Selby P; Howell A; Evans DG
    Br J Cancer; 2011 Jun; 105(1):22-7. PubMed ID: 21654687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
    BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
    Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
    J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
    Finch A; Evans G; Narod SA
    Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
    Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
    Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
    J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
    Marchetti C; Iadarola R; Palaia I; di Donato V; Perniola G; Muzii L; Panici PB
    Menopause; 2014 Jul; 21(7):763-8. PubMed ID: 24253485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Stopfer JE; Rebbeck TR
    J Natl Compr Canc Netw; 2006 Feb; 4(2):177-82. PubMed ID: 16451773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
    Finch A; Narod SA
    Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.